pyrazolopyrimidine

CLM3, a pyrazolopyrimidine derivative, functions as a multitargeted tyrosine kinase inhibitor. It exhibits antiproliferative and proapoptotic activities on endothelial and cancer cells, activities that are synergistically enhanced by SN38. The primary mechanism of action for CLM3 involves the inhibition of phosphorylation in tyrosine kinases such as VEGFR-2, EGFR, and RET, along with their associated signaling pathways.

DDO-2728 is a selective pyrazolopyrimidine ALKBH5 inhibitor with an IC50 of 2.97 μM. It enhances the level of N6-methyladenosine (m6A) modification in acute myeloid leukemia (AML) cells and exhibits antiproliferative activity in these cells. Additionally, it demonstrates antitumor efficacy in MV4-11 xenograft models.

UNC569 (UNC 569) is a selective inhibitor of URAT1, a transporter in the kidney that regulates uric acid excretion from the body. It is also a selective uric acid re-absorption inhibitor. UNC569 could normalize the amount of uric acid excreted by gout patients previously classified as under-excretors.

Efflux inhibitor-1 is a pyrazolopyrimidine efflux inhibitor. Efflux inhibitor-1 selectively targets toward ABCG2 BCRP over ABCB1 with IC 50 s of 0.45 μM and 2.17 μM, respectively .

ALK2-IN-5, a pyrazolopyrimidine compound, serves as an inhibitor of ALK2 and FGFR, targeting disorders linked with their activity, including cancer [1].